Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Portable Nanoplasmonic Imager Detects Sepsis Faster

By HospiMedica International staff writers
Posted on 05 Feb 2020
A highly portable device based on a nano-scale optical biosensor can rapidly detect inflammatory biomarkers in a patient's bloodstream.

Developed at Ecole Polytechnique Fédérale de Lausanne (EPFL; Switzerland), Hospital Universitari Vall dHebron (Barcelona, Spain), and Universitat Autònoma de Barcelona (UAB, Spain), the new device employs a gold-based metasurface that concentrates light around billions of nanoholes. More...
Nanoparticles that capture the sepsis biomarkers procalcitonin (PCT) and C‐reactive protein (CRP) are distributed on the metasurface, and those that have captured biomarkers are trapped in the nanoholes. When an LED is applied, they partially obstruct the light passing through the perforated metasurface, allowing detection with a CMOS camera.

In field studies with a wide range of patient samples with sepsis, noninfectious systemic inflammatory response syndrome (SIRS), and healthy subjects, the device achieves an outstanding limit of detection of 21.3 pg mL−1 for PCT and 36 pg mL−1 for CRP. The results were validated against clinical diagnosis and currently used immunoassays, providing a performance level equivalent to the gold‐standard laboratory tests. Importantly, the plasmonic imager can enable identification of PCT levels typical of sepsis and SIRS patients in less than 15 minutes. The study was published on January 23, 2020, in Small.

“The device proved to be particularly suitable for on‐site operation due to its portability, inexpensive off‐the‐shelf optical components, and because it does not involve any moving parts or complex microfluidic elements prone to clogging,” concluded lead author Alexander Belushkin, PhD, of the EPFL Institute of BioEngineering, and colleagues. “Importantly, the sensor chips and bioassay reagents can be stored in the fridge stably over weeks and unlike previously reported optical detection schemes, do not require fluorescent tags that can be expensive, unstable, and difficult to produce.”

Sepsis is the primary cause of death in hospitals, and one of the ten leading causes of death worldwide, claiming a life every four seconds. It is associated with the body's inflammatory response to a bacterial infection and progresses extremely rapidly: every hour that goes by before it is properly diagnosed and treated increases the mortality rate by nearly 8%. Time is critical with sepsis, but the tests currently used in hospitals can take up to 72 hours to provide a diagnosis.

Related Links:
Ecole Polytechnique Fédérale de Lausanne
Hospital Universitari Vall dHebron
Universitat Autònoma de Barcelona



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.